Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA.
Division of Biometrics VII, Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
J Biopharm Stat. 2022 May 4;32(3):474-495. doi: 10.1080/10543406.2022.2078346. Epub 2022 Jul 7.
We present a Bayesian framework for sequential monitoring that allows for use of external data, and that can be applied in a wide range of clinical trial applications. The basis for this framework is the idea that, in many cases, specification of priors used for sequential monitoring and the stopping criteria can be semi-algorithmic byproducts of the trial hypotheses and relevant external data, simplifying the process of prior elicitation. Monitoring priors are defined using the family of generalized normal distributions, which comprise a flexible class of priors, naturally allowing one to construct a prior that is peaked or flat about the parameter values thought to be most likely. External data are incorporated into the monitoring process through mixing an a priori skeptical prior with an enthusiastic prior using a weight that can be fixed or adaptively estimated. In particular, we introduce an adaptive monitoring prior for efficacy evaluation that dynamically weighs skeptical and enthusiastic prior components based on the degree to which observed data are consistent with an enthusiastic perspective. The proposed approach allows for prospective and pre-specified use of external data in the monitoring procedure. We illustrate the method for both single-arm and two-arm randomized controlled trials. For the latter case, we also include a retrospective analysis of actual trial data using the proposed adaptive sequential monitoring procedure. Both examples are motivated by completed pediatric trials, and the designs incorporate information from adult trials to varying degrees. Preposterior analysis and frequentist operating characteristics of each trial design are discussed.
我们提出了一个贝叶斯框架,用于序贯监测,允许使用外部数据,并可应用于广泛的临床试验应用中。该框架的基础是这样一种观点,即在许多情况下,用于序贯监测和停止标准的先验指定可以通过试验假设和相关外部数据的半算法副产品来完成,简化了先验提取的过程。监测先验使用广义正态分布族来定义,广义正态分布族是一类灵活的先验分布,自然可以构建一个关于最可能参数值的尖峰或扁平的先验。外部数据通过使用可以固定或自适应估计的权重将先验怀疑论者与热情的先验混合到监测过程中。特别是,我们为疗效评估引入了一种自适应监测先验,根据观察数据与热情观点的一致性程度,动态地权衡怀疑论者和热情论者的先验成分。所提出的方法允许在监测过程中前瞻性和预指定地使用外部数据。我们为单臂和双臂随机对照试验说明了该方法。对于后者,我们还使用所提出的自适应序贯监测程序对实际试验数据进行了回顾性分析。这两个例子都是由已完成的儿科试验引发的,并且设计在不同程度上结合了成人试验的信息。讨论了每个试验设计的后验分析和频率论操作特征。